Theriva Biologics, Inc.
TOVX
$0.31
-$0.01-3.58%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -57.02% | 16.28% | 18.92% | -134.02% | -63.54% |
| Total Depreciation and Amortization | -28.95% | -33.33% | -30.77% | 3.13% | 18.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 134.99% | -168.02% | 115.64% | 289.88% | 1,102.19% |
| Change in Net Operating Assets | -169.93% | -14,400.00% | -209.55% | -88.36% | 17.70% |
| Cash from Operations | -36.50% | 2.56% | 28.28% | -32.51% | 11.31% |
| Capital Expenditure | -1,500.00% | -- | 100.00% | 100.00% | 88.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,500.00% | -- | 100.00% | 100.00% | 88.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 83.58% | -- | -- | -- | -235.00% |
| Issuance of Common Stock | 263.80% | -- | -88.71% | 371,500.00% | -14.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 284.15% | -- | 100.48% | 371,500.00% | -16.99% |
| Foreign Exchange rate Adjustments | -358.33% | 344.74% | -261.84% | 254.55% | 119.05% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 223.02% | 67.66% | 39.75% | 94.18% | 8.75% |